Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir

Form: Tablet

Strength: Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet)

Reference Brands: Viekira Pak® (US); Viekirax® + Exviera® (EU)

Category: Hepatitis

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is a fixed-dose combination therapy used in the treatment of chronic Hepatitis C genotype 1. Marketed as Viekira Pak® in the US and Viekirax® + Exviera® in the EU, this regimen includes four direct-acting antivirals that target multiple stages of the HCV replication cycle. It offers a non-interferon-based treatment, often in combination with ribavirin. EMA and FDA approved, it’s a key option for B2B pharmaceutical partners sourcing branded and generic HCV therapies. Suitable for hospital, retail, and tender supply in regulated and semi-regulated markets. Available in tablet form with clearly defined daily dosing.